These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9100315)

  • 1. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility.
    Gonzalez FJ
    Reprod Toxicol; 1997; 11(2-3):397-412. PubMed ID: 9100315
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
    Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
    Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of individual susceptibility in cancer burden related to environmental exposure.
    Bartsch H; Hietanen E
    Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):569-77. PubMed ID: 8781385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytochrome P-450 genetic polymorphisms in oral carcinogenesis.
    Hernando-Rodriguez M; Rey-Barja N; Marichalar-Mendia X; Rodriguez-Tojo MJ; Acha-Sagredo A; Aguirre-Urizar JM
    J Oral Pathol Med; 2012 Jan; 41(1):1-8. PubMed ID: 21793938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response.
    Autrup H
    Mutat Res; 2000 Jan; 464(1):65-76. PubMed ID: 10633178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic genetic polymorphisms and susceptibility to lung cancer.
    Bouchardy C; Benhamou S; Jourenkova N; Dayer P; Hirvonen A
    Lung Cancer; 2001 May; 32(2):109-12. PubMed ID: 11325480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
    Gonzalez FJ
    Birth Defects Orig Artic Ser; 1990; 26(1):17-42. PubMed ID: 2224077
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphism and their contribution to cancer susceptibility.
    Conforti-Froes N; el-Zein R; Au W
    Cad Saude Publica; 1998; 14 Suppl 3():7-13. PubMed ID: 9819460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the gene polymorphisms of oxidative metabolism enzyme of exogenous chemicals and the susceptibility to neoplasms].
    Xia G; Hu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 42(12):1439-1446. PubMed ID: 29317586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and biochemical issues in the molecular epidemiology of cancer.
    Snyder R; Hong JY
    IARC Sci Publ; 2004; (157):51-69. PubMed ID: 15055290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations.
    Kaderlik KR; Kadlubar FF
    Pharmacogenetics; 1995; 5 Spec No():S108-17. PubMed ID: 7581479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis.
    Gonzalez FJ; Kimura S
    Cancer Lett; 1999 Sep; 143(2):199-204. PubMed ID: 10503904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolizing enzyme genotype and risk for upper aerodigestive tract cancer.
    Lazarus P; Park JY
    Oral Oncol; 2000 Sep; 36(5):421-31. PubMed ID: 10964048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and Phase II enzyme polymorphisms and childhood cancer.
    Swinney R; Hsu S; Tomlinson G
    J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of candidate genes for population studies.
    Caporaso N
    IARC Sci Publ; 1999; (148):23-36. PubMed ID: 10493246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
    Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar.
    Gonzalez FJ
    Cancer Res; 1995 Feb; 55(3):710-5. PubMed ID: 7834645
    [No Abstract]   [Full Text] [Related]  

  • 19. [Genetic variations in the metabolism of environmental toxins].
    Autrup H
    Ugeskr Laeger; 2005 May; 167(20):2173-6. PubMed ID: 15987077
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.